



## Knalysis Technologies Forges Partnership with New Frontier Data

TORONTO, May 23, 2018 -- Knalysis Technologies (“Knalysis”), a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”), has recently completed an exciting new project with New Frontier Data, the leader in business intelligence for the cannabis industry. New Frontier Data provides vetted, objective reporting and analysis regarding all aspects of the cannabis vertical.

This past month the Company sponsored New Frontier Data’s *Canada Cannabis Report: Industry Outlook 2018* which is now available for download at <https://newfrontierdata.com/marketresearch/>.

The report, the first for the Canadian market, includes capital and performance data; detailed demand forecasts; regulatory timeline impacts; top LP size considerations; consumer preferences and other medical marketing data that can assist industry stakeholders.

Knalysis currently tracks a variety of datasets from the cannabis industry in both Canada and the U.S., including product efficacy in treating symptoms and ailments and also how medical cannabis reduces and replaces the need for opiates and other pharmaceuticals. Knalysis and New Frontier Data are already looking ahead toward expanding data streams to support the global market.

“This partnership is exciting for Knalysis,” says Knalysis’ President, Paul Methot. “New Frontier Data is the dominant player in the cannabis data space. We love working with the team and look forward to a long-term collaboration to bring our data to bear as Knalysis continues to track, optimize and prove the efficacy of medical marijuana.”

“We have thoroughly enjoyed working with Knalysis on our Canada Cannabis Report. The insights that their data brings to the Canadian medical market are instrumental to the work we are doing at New Frontier Data and we look forward to continuing to work with their team of innovators,” said Giadha Aguirre De Carcer, CEO and founder, New Frontier Data.

### **About Knalysis:**

Knalysis Technologies is a subsidiary of Canada House Wellness Group Inc., a publicly-traded Canadian company with one of the largest networks of cannabis clinics in Canada. We envisioned a need for health technology connecting every aspect of the medical marijuana field, and pioneered software to seamlessly link physician, provider, and patient. Purpose-built in our own clinics, Knalysis’ suite of software has been battle-tested with thousands of patients for over four years; treating a broad range of ailments and symptoms.

### **Canada House Wellness Group Inc.**

Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit <https://www.canadahouse.ca>. or [www.sedar.com](http://www.sedar.com)

### **About New Frontier Data:**

New Frontier Data is an independent, technology-driven analytics company specializing in the cannabis industry. It offers vetted data, actionable business intelligence and risk management solutions for investors, operators and policymakers. New Frontier Data’s reports and data have been cited in over 65 countries around the world to inform industry leaders. Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with additional offices in Denver. For more information or media inquiries please visit [www.newfrontierdata.com](http://www.newfrontierdata.com) or emails us at [info@newfrontierdata.com](mailto:info@newfrontierdata.com).

New Frontier Data does not take a position on the merits of cannabis legalization. Rather, its mission and mandate is to inform cannabis-related policy and business decisions through rigorous, issue-neutral and comprehensive analysis of the legal cannabis industry. **For more information about New Frontier Data please visit: [www.newfrontierdata.com](http://www.newfrontierdata.com).**

**Cautionary Statement Regarding Forward-Looking Information.** Certain statements within this news release pertaining to the Company constitute “forward-looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward-looking statements”. Such “forward-looking

statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward-looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

**For further information, please contact:**

**Boom Capital Markets**

Steve Low

647-620-5101

[steve@boomcapitalmarkets.com](mailto:steve@boomcapitalmarkets.com)

**Canada House Wellness Group, Inc.**

Larry Bortles

1-844-696-349

[lbortles@canadahouse.ca](mailto:lbortles@canadahouse.ca)